Method of diagnostics of menstrual dysfunction against background of polycystic ovarian syndrome by immature girls |
|
|
IPC classes for russian patent Method of diagnostics of menstrual dysfunction against background of polycystic ovarian syndrome by immature girls (RU 2535096):
Method for early prevention of gestational complications / 2530624
Method involves detecting a threatening miscarriage and a carrier state of the polymorphism in the gene of folate metabolism, as well as a CD54+ lymphocyte ratio, lactoferrin and β-subunit of human chorionic gonadotropin (β-HCG) levels in venous blood of a pregnant woman from the onset of pregnancy to the end of the first trimester. That is followed by calculating a prognostic index (PI) by formula: PI=0.7199X1+1.2552X2-0.00653X3-0.0009X4+0.0722X5+1.1277, wherein X1 is the threatening miscarriage, yes/no (1/0); X2 is the polymorphism in the gene of folate metabolism, yes/no (1/0); X3 is the CD54+ lymphocyte ratio, %; X4 is the lactoferrin level, ng/ml; X5 is the concentration of the free β-subunit of human chorionic gonadotropin (β-HCG), ng/ml. If PI<0, the gestational complications are predicted, while PI>0 enables stating a low risk of pathological conditions accompanying pregnancy. A sensitivity of the presented method makes 81.2%, its specificity is 85.1%. The method effectiveness is 83.2%.
Diagnostic technique for renal functional reserve / 2528903
Invention refers to medicine. Substance of the early diagnostic technique for chronic renal disease consists in using a dosage range of dopamine of 1 to 3 mcg/kg of body weight and a standard water load of 200 ml. No glomerular filtration rate increase testifies to the presence of early signs of chronic renal disease.
Diagnostic technique for clinically latent hypercorticoidism in patients suffering from stype 2 diabetes mellitus or obesity / 2521387
First stage comprises a night suppressive test with dexamethasone 1 mg with a test considered to be positive, if plasma cortisol measured at 8.00 in the next morning exceeds 50 nmole/l. If the first stage has a positive result, the second stage is performed 1-2 days later. At the second stage, blood plasma cortisol at 24.00, daily urine free cortisol, a coefficient of circadian rhythm of cortisol secretion are determined on the same day. If at least two of the three test results are above normal: plasma cortisol at 24.00 is more than 207 nmole/l, daily urine free cortisol is more than 180 mcg/day, coefficient of circadian rhythm of cortisol secretion is more than 50%, hypercorticoidism syndrome is diagnosed. The presented technique provides higher accuracy and simplifies diagnosing of the given disease.
 Solid phase enzyme-immunoassay (eliza) for vascular endothelial growth factor (vegf) / 2517301
Invention relates to the field of immunology, namely to enzyme-immunoassay, in particular to a method of detecting forms of vascular endothelial growth factor (VEGF) with a size more than 110 amino acids in a biological sample. The method includes the following stages: contact and incubation of the biological sample with an uptake reagent, immobilised on a solid substrate, where the uptake reagent contains a monoclonal antibody, which recognises and specifically binds with residues, in quantity more than 110, from human VEGF; separation of the biological sample from the immobilised uptake reagents; contact of the immobilised molecular complex of the reagent of the uptake-target with detected antibody, which binds with VEGF domains, responsible for binding with KDR and/or FLT1 receptor, or which binds with an epitope in VEGF1-110; measurement of the level of VEGF110+, bound with reagents of the uptake, with application of means of detection for the detected antibody. Set of immune assay reagents for detection of VEGF110+ forms in the biological sample. An antibody 5C3, obtained from hybridoma 5C3.1.1 with a depositary number PTA-7737, with the said antibody 5C3 binding VEGF110+ forms, including VEGF121+. Hybridoma 5C3.1.1, deposited in ATCC with the depositary number PTA-7737, to obtain the monoclonal antibody 5C3.
Method for determining degree of severity of chronic obstructive pulmonary disease / 2516971
Blood is examined. The steroid hormones cortisol (nmole/l) and DHEA-S (mcmole/l), as well as the oxidative stress values - oxidative modified proteins (OMP, nM/mg, protein), malondialdehyde (MDA, nM/ml) and SH groups mg% are evaluated. The forced expiratory volume 1(%) FEV1 is calculated by formula on the basis of the derived values. If the derived FEV1 is within 50% to 80%, the presence of a moderate degree of chronic obstructive pulmonary disease; the FEV1 being within the range of 30 to 49% means a severe degree of chronic obstructive pulmonary disease (COPD), and the derived value being less than 30% shows an extremely severe degree of COPD.
Method for prediction of risk of early development of atherosclerosis in patients with chronic prostatitis / 2504782
Blood serum of the younger patient suffering chronic prostatitis is examined for total testosterone, sex hormone-binding globulin to calculate a free testosterone index; high-density lipoproteins and triacylglycerides are determined, and an atherogenic index is calculated by formula. If the atherogenic index is <3.7, a high risk of the early development of atherosclerosis is predicted.
 Method for prediction of recurrent non-small-cell lung cancer / 2498305
What is involves is the histological examination of tissue fragments taken from the extracted lung with primary, intermediate and segmental bronchi at 4-5 cm from the tumour, and disregeneration change cases are determined in the respiratory bronchial epithelium, including: basal cell hyperplasia (BCH), squamous metaplasia (SM) and if observing a combination of basal cell hyperplasia and squamous metaplasia (BCH+SM+) in the respiratory bronchial epithelium adjacent to the tumour, a risk of developing the recurrent non-small-cell lung cancer is predicted.
 Method for prediction of recurrent cervical cancer / 2485523
Method for prediction of recurrent cervical cancer involves biochemical daily urine analysis to determine daily urine androsterone and etiocholanolone to be related; if the relation is 0.75 mg/day or less, the recurrent disease is predicted for the first 2 years, and if the relation exceeding 0.75 mg/day, a prolonged recurrence-free period up to 10 years or more is predicted.
 Method for aromatase activity test / 2481587
Blood serum is examined for lutropin, follitropin, oestradiol, total testosterone and free testosterone levels before and 48 hours after the oral administration of 450 aromatase inhibitor, letrozole 10 mg, and the variations of lutropin and follitropin, as well as of the oestradiol/total testosterone and oestradiol/free testosterone relations are used to asses aromatase activity in points assigned by a certain way to consider low aromatase activity shown by total score 0 to 7 points, normal aromatase activity - 8 to 14 points, and high aromatase activity - 15 points or more.
Method for specifying directionality of pathological process in mucinous gastric carcinoma / 2480771
In males with mucinous gastric carcinoma after a curative resection to the extent of gastrectomy, tumor tissue is analysed for the level of testosterone. If the tissue value is 7.8±0.6 ng/g, process generalisation within 6 to 12 months is predicted; the level of tissue testosterone 174.5±15.6 ng/g enables predicting the favourable clinical course of the process, prolongation of the patient's life.
 Method for liposuction injury evaluation / 2535091
Lipoaspirate is collected into a container; a liquid portion of the lipoaspirate is sampled from the bottom of the container and diluted in normal saline; that is followed by red blood count in the Goryaev's chamber in five large squares, each of which consists of 16 small squares by formula:
Method for prediction of clinical course of atrophic anaemia following splenectomy / 2535059
Splenectomy is followed by determining its weight, carrying out morphometric measurements of an average area of the white pulp of the lymphoid organ in histological sections stained by haematoxylin and eosin. These values are taken into account to calculate a mass of the white pulp by formula: m=mspleen×D%/100%, wherein m is the mass of the white pulp (g), mspleen is the total mass of the spleen (g), D is the average area of the white pulp, %. If the calculated value is ≤8.4 g, the favourable prognosis for atrophic anaemia is established, and if the value is >8.4 g, the unfavourable prognosis of the disease is stated.
 Methods and sets for predicting risk of infusion responses and antibody-mediated loss of response in therapy with pegylated uricase by monitoring uric acid content in blood serum / 2535038
Group of inventions relates to medicine, namely to therapeutic treatment of gout and prevention of accompanying side effects and complications in patients. method of prevention and prediction of risk of infusion responses in case of intravenous introduction of pegylated uricase to patients with gout consists in determination of uric acid content in patient's blood serum with the following indication to cessation of therapy at the level of approximately 4 mg/dl. Claimed method also makes it possible to identify risk group of patients, who receive pegylated uricase, with reduction of treatment efficiency due to formation of antibodies and higher risk of infusion response development.
Method for assessing activity of inflammatory process / 2535026
Venous blood samples are examined to measure rod nuclear cells according to clinical blood analysis findings, C-reactive protein according to biochemical blood assay findings, fibrinogen according to coagulologic analysis findings; tracheal aspirate samples are examined to measure neutrophil leukocytes according to cytologic analysis findings, isolated gram-positive and gram-negative clinical strains of microorganisms or a combination thereof and a quantity of a rate of growth of the microbial biomass. The prepared blood and tracheal aspirate values are analysed and assessed according to the 3-point scale. The total score is calculated, and the derived value is used to assess the inflammatory process activity: 6-9 points - low: 10-14 - medium; 15-18 - high.
 Method of individual quantitative assessment of risk of hypertension development / 2535025
Invention relates to medicine, namely to therapy, cardiology, pathophysiology, biochemistry, pharmacology, and is intended for assessment of degree of hypertension development. Invention is based on discriminant analysis with application of a set of indices, coefficients and constants of displacement for particular category of patients, namely for smoking and non-smoking people. Value of discriminant function is calculated to determine presence or absence of hypertension. If value of discriminant function (d) is from -2 to 0, risk of hypertension development is estimated as low, if d is higher than 0, risk if hypertension development is estimated as increased in 100% of cases in smoking people and in 70% of cases in non-smoking people, and if d value is higher than 3, risk of hypertension development is estimated as high in 100% of cases both in smoking and non-smoking people. After that individual quantitative value of degree of risk of development or absence of hypertension in accordance with belonging to groups by smoking is determined: absence of hypertension is determined by formula RE=1/(1+EXP(d))*100%, where (d) is value of discriminant function, and presence of hypertension is determined as 100-RE(%). Application of method will make it possible to carry out individual assessment of hypertension development at early stages, to monitor health condition to people, who are redisposed to disease, as well as to use method in assessment of treatment efficiency in patients with achieved target levels of arterial pressure. Invention sensitivity constitutes 98.5% for smoking people and 88.6% for non-smoking people.
Method of treating chronic calculous prostatitis / 2534853
Method involves a course of 5-7 pulse ultrasonic procedures having an intensity of 0.2-0.4 W/cm2 of 5-7 minutes daily. That is combined with enzyme therapy with Longidaza 3,000 units 2 times a week for 1 month. Besides, Trilon B rectal suppositories 1,000 mg and Dimexidum 200 mg are administered daily for the night for 3 months. The bacteria are detected by a microscopic and microbiologic examination of ejaculate that is followed by a 4-6-week antibacterial therapy by administering an antibacterial preparation taking into account the microflora sensitivity.
Method for monitoring individuals with risk of early atherosclerosis and suffering from type 2 diabetes mellitus / 2533836
Clinical medical history data are determined as follows: body weight index (BWI), kg/m2; waist circumference (WC), hip circumference (HC), waist-to-hip ratio, type 2 diabetes mellitus diagnosed in close relatives, arterial hypertension (AH) diagnosed. The laboratory data are measured as follows: plasminogen activator inhibitor-1 (PGAI-1), nmole/l; nitrogen oxide (NO) metabolites, %; resistin, ng/ml; insulin resistance (IR), mIU/ml; triglycerides (TG), mmole/l; high density lipoprotein cholesterol (HDLPC), mmole/l; fibrinogen, mg/dl; impaired fasting glucose (IFG), mmole/l; glycosylated haemoglobin (HbAlc), %; impaired glucose tolerance (IGT), mmole/l; homocystein (HC), mcmole/l; TNF-α, pg/ml; C-reactive protein, mg/l; endothelin and fibrinogen. The derived values are scored. The total score is used to determine a risk of atherosclerosis in the patients suffering from type 2 diabetes mellitus: extremely high, high, moderate and low. Taking into account the detected degree of risk, a dosage of aspirin and statins are determined, as well as a monitored mode of blood lipids, urinary albumin and blood creatinine is specified.
Diagnostic technique for erosiogenic activity of oral fluid in patients suffering from oesophageal oral reflux accompanying gastroesophageal reflux disease / 2533561
Invention refers to medicine, namely dentistry, and concerns a diagnostic technique for the erosiogenic activity of the oral fluid in patients suffering from gastroesophageal oral reflux accompanying gastroesophageal reflux disease. The diagnostic technique for the erosiogenic activity of the oral fluid in the patients suffering from gastroesophageal oral reflux accompanying gastroesophageal reflux disease involves taking the oral fluid sample at 7 a.m., 2 p.m., 7 p.m., 11 p.m., and 3 a.m. next day and analysing the chemical property of the oral fluid sampled from the patients with or without dental erosions accompanying gastroesophageal reflux disease; the oral fluid is additionally analysed to measure chlorides and bicarbonates, variations of which are foremost observed at 11 p.m. and 3 a.m. next day; if the chloride amount measured is above a reference, while the bicarbonates are found to be less than that, the oral fluid is stated to be erosiogenic, while the chloride and bicarbonate amounts falling within the reference ranges allow considering the oral fluid to be non-erosiogenic with underlying gastroesophageal reflux disease.
 Diagnostic technique for disturbed thrombocyte aggregation accompanying mucoviscidosis in children / 2533287
Invention represents a diagnostic technique for the disturbed thrombocyte aggregation accompanying mucoviscidosis in children involving a thrombocyte aggregation test using the Multiplate aggregometer inducers. Trays with a magnetic mixer and electrodes are added with NaCl 400 mcl at 37°C and immediately added with whole blood 400 mcl from a hirudin test tube, incubated in the chamber for two minutes; the tray is added with 30 mcl of an aggregation inducer specified in a group: soluble thrombin receptor - peptid-6, adenosine diphosphate, arachidonic acid. The thrombocyte aggregation rate is displayed on the screen in the form of a curve, and the sub-curve area U is automatically calculated; the sub-curve area U shows the thrombocyte aggregation state as compared to reference values in the group of healthy children; if the threshold area U has appeared to exceed the reference, the thrombocyte hyperaggregation, while the threshold area U being less than the reference, the thrombocyte hypoaggregation is stated.
Method for acquiring samples for spectral biochemical blood analysis / 2533258
Method for acquiring samples for the spectral biochemical blood analysis involving preparing and drying blood serum and extracting for the chromatographic examination differs by the fact that a process of a dry matter of blood serum obtaining is performed with stirring constantly at a temperature of 50-60°C for 21-27 hours to produce the dry matter in the form of a plug compacted in the centre and coated with a superficial film; the plug is perforated with a sterile and chemically intact object; 85% methanol is added to a test tube containing the dry matter. The prepared mixture is placed into the stirring device again at a temperature of 48-52°C for 21-27 hours and compacted in a centrifuge at an acceleration of 11500-12500 g. The prepared sample is added to an auto-sampler test tube of a liquid chromatograph in an amount of 3/4 - 2/3 volumes of the test tube.
Method for predicting hallucino-delirious forms of psychoses of cerebro-atherosclerotic genesis / 2244303
One should isolate DNA out of lymphocytes of peripheral venous blood, then due to the method of polymerase chain reaction of DNA synthesis one should amplify the fragments of hSERT locus of serotonin carrier gene and at detecting genotype 12/10 one should predict the risk for the development of hallucino-delirious forms of psychoses of cerebro-atherosclerotic genesis.
|
FIELD: medicine. SUBSTANCE: for immature girls after day 3-5 of menstrual cycle a level of Anti-Mullerian Hormone is determined in blood serum by method of enzyme multiplied immunoassay (ELISA), and if its value exceeds 5.2 ng/ml the menstrual dysfunction is diagnosed against the background of polycystic ovarian syndrome. EFFECT: use of specified method increases accuracy of diagnostics and execution of the appropriate remedial measures relating polycystic ovarian syndrome. 6 ex
The invention relates to medicine, namely gynecology and endocrinology, and can be used for early detection of menstrual function (MFD) arising on the background of polycystic ovary syndrome (PCOS). Syndrome giperandrogenii (HA) is one of the most pressing problems in endocrinology and gynecology. The importance of this disease in the first place is determined by a high prevalence in the population and proven Association with metabolic disorders, diabetes mellitus type 2, cardiovascular disease and infertility (Peterkova C. A., Demicheva T. C., 2005). The manifestation of symptoms HA can occur at different ages, but most women first prerequisite for the development of the disease manifest themselves in the period of puberty. Syndrome HA includes the following diseases: polycystic ovary syndrome (PCOS), non-classical form of congenital adrenal hyperplasia (ULN), isolated androgen dermopathy. NC-ULN is an exception to this series due to the fact that the pathogenesis of this disease is known. The rest have no clear data on the pathogenesis and diagnosis of exclusion, or in other words - do not have a clear definition (Marcinkowska centuries, beetle C. I., 2007). Of particular interest is the doctrine of factors, which affect the follicle Genesis and can prevent the onset of ovulation, leading to cystic degeneration of ovaries. Some researchers believe that violations of follicle Genesis with PCOS in the largest extent due to rising androgens ovarian origin. In turn, high levels of androgens inhibit the maturation of follicles at different stages and lead to the formation of a typical enlarged ovaries with multiple small follicles. Modern international diagnostic criteria include the following characteristics: first, the presence of anovulation, which is expressed in oligomenorrhea or amenorrhea, secondly, in the signs of giperandrogenii ovarian dysfunction, which is expressed clinically (hirsutism) or change of biochemical parameters (increased levels of androgens) and, thirdly, in the morphological characteristics multifollicular ovaries (determined by ultrasound). The presence of two of these three signs is a modern diagnostic criteria of PCOS (The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, 2004). Method of diagnosis of menstrual dysfunction arising on the background of polycystic ovary syndrome based on clinical symptoms are very nonspecific, because menstrual irregularities can occur in puberty the second period frequently enough to wear with this functional transient character, being caused by the imperfection and immaturity of the reproductive system. Similar violations at this age may vary depending on the duration of the formation of menarche, emotional status of the adolescent, the degree of mental and physical activity, the impact of various negative factors internal and external environment, to which the body of a teenage girl in this age period is the most vulnerable. A known method for the diagnosis of polycystic ovary syndrome, namely, that determine the presence of the following symptoms: ovarian enlargement, rhythm menses, anovulation, and hirsute syndrome, obesity, which are obligate (unstable) features (Permyakov N. K. Aliyev, E. A., 1989). A known method for the diagnosis of polycystic ovary syndrome on the basis of tables of clinical and laboratory findings (Krupko-Bolsova Y. A., Kornilov, A. I., 1990). The way objectivesare diagnosis of the disease, but has some significant drawbacks, including the following: characteristics of the NFM in this disease does not cover the whole spectrum disorders and simplified; the characteristic of the degree of hirsutism biased and does not reflect the transient States; - the use of the sign "obesity 1-St and 2-nd degree" biased, as is obligatory character; incorrect use is of basal temperature for the differential diagnosis of the severity of the disease, both mono-and biphasic basal body temperature can occur at any level of severity of the disease; not an information indicator type smear - estrogenic or androgenic; and the definition of gonadotropin and sex hormone excretion in the urine is an outdated method and recognized as ineffective. In this regard, there is a need to develop an objective method for early diagnosis of emerging PCOS in adolescent girls for selecting the optimal treatment programs and monitoring their effectiveness. Attempts were made to diagnose PCOS on the basis of sonographic picture of the ovaries, the interpretation of the results of which can be quite ambiguous. Because up to 16-17 teenagers 80% of cycles are anovulatory, echographic signs multifollicular ovaries and the absence of a dominant follicle can be considered a variant of the physiological norm, as with regular menstrual cycle, and for various disorders of the menstrual cycle in the pubertal period (Saidova R. A., 1999). Adolescent polycystic ovaries must be differentiated from multikilogram. Multiple cysts in the ovaries are normal physiological phenomenon in puberty, they regress in parallel with the development of ovulatory function. For increasing t is knosti sonographic diagnosis of PCOS quantitative metrics S (normal is 3.5), the increase of which is important for diagnosis of PCOS. The vast majority of patients (91%) revealed a decrease in the anteroposterior size of the uterus while increasing the size and volume of the ovaries (98%). In 90% of patients with ovarian-uterine index is more than 3.5. Also unsuccessful were attempts to link the excess production of certain androgens with the development of ovarian dysfunction. When studying a wide range of androgens and their precursors syndrome HA adolescent girls are shown the absence of universal hormonal markers HECTARES; it is revealed that up to 15% of cases of this disease proceeds without hyperandrogenemia, and the rate of increase of androgens does not correlate with severity of clinical symptoms (Bogdanov P.F., Karev, M. A., 2010). Because according to modern literature PCOS develops in the body of girls in breach of the physiological rhythm of production of gonadoliberin, then tried to determine the ratio of LH and FSH, which reflects the state of the higher regulatory centers (Trent M. E., Rich M V, Austin, S. B., 2003). Normal LH/FSH before menarche is always less than 1, more than a year after menarche varies from 1 to 1.5, more than 2 years - from 1.5 to 2 (Carolina C. F., 2001). If women of childbearing age index value of LH/FSH > 2 is pathognomonic for PCOS, spokesdog LH/FSH more than 1.5 is pathognomonic for PCOS. At the same time, only 20% of surveyed teenage girls index of LH/FSH was more than 1.5 but less than 2, i.e. data diagnostic method has low accuracy (Bezuglova N. G, 2005). Also known a method of diagnosis, selected as a prototype (the Seagull Century K., Matytsin L. A., Otenko B. A. a method for the diagnosis of polycystic ovary syndrome in adolescent girls, 1999), providing for the determination of the level of hormones in the blood in girls before menarche, the evaluation of the numerical values of the degree of hirsutism, and ovarian-uterine index, and then calculate the severity of PCOS according to the formula: y=0,02012p1+p(t)+0,07243 R-1,12114 p(tm)-0,04008 b+0,07146 gir+0,07565 s+3,74045, where y is the severity of the disease; p1 - prolactin levels determined in the blood immunofluorescence method, ng/l; p - level of progesterone in blood serum, nmol/l; t is the level of testosterone in blood serum, nmol/l; b - the level of testosterone-estradiol (binding globulin), nmol/l; gir - the degree of hirsutism; s - ovarian-uterine index; tm is the thickness of the uterus, mm; thus, if the value of 0.5, is considered a healthy girl; 0,5<y<1.0 to belong to the risk group for the development of PCOS; 1,0<y<2.0 to diagnose mild currents PCOS; 2,0<y<3,0 - medium flow PCOS; y>3,0 - severe PCOS. The disadvantages of this method are: - its laboriousness, - arithmetic is Kai complexity for outpatient physician, - is not taken into account the high variability of prolactin and progesterone depending on the phase of the menstrual cycle, is not justified by binding to hirsute, because the weight of androgen-dermopathy not correlated with the severity of ovarian dysfunction, as determined by the activity of the corresponding receptor system. These shortcomings of the prototype method reduce its accuracy and reliability. The objective of the invention: development of more accessible, accurate, reliable method for the diagnosis of disorders of menstrual function on the background of polycystic ovary syndrome in adolescent girls. This goal is achieved by the fact that adolescent girls on day 3-5 of the menstrual cycle carried out the determination of the level antimullerian hormone in serum enzyme-linked immunosorbent assay, and if it is higher than the 5.2 ng/ml, diagnose menstrual function on the background of polycystic ovary syndrome. The technical result from the use of the method: improving accuracy, reducing errors, and the extension of the age range surveyed patients that will allow timely appropriate treatment PCOS, which will further contribute to strengthening reproductive health of future women. Antimullerian hormone or ing birouste substance Muller (AMG/IVM, AMH/MIS) is a dimeric glycoprotein belongs to the family of β-transforming growth factors. Women from birth to menopause AMH is produced by the granular cells of the ovaries. In women, the level of AMH in serum is relatively low until the onset of puberty. The concentration of AMS in women correlates with the number of antral follicles with age best reflects the decrease in reproductive function in healthy women with proven fertility. Ovarian reserve of the patient according to the results of the triple test (inhibin b, AMS and FSH on day 3 of the cycle) is compared with the expected provision for this age, which allows you to control reproductive function. Synthesis AMG occurs in granular cells of primary follicles. The maximum number of AMG in preantral and antral follicles with a diameter of 4 mm and is not expressed in dominant follicles. After selection of the dominant follicle expression of AMH decreases. If the number of antral follicles decreases the expression of AMH is also reduced. With the further development of the follicle its synthesis is reduced and virtually absent (FSH-dependent stage) when the size of follicles larger than 8-9 mm in normal ovaries, which is a necessary condition for selection of the dominant follicle. There are two main actions of AMH in the ovary in which erwich, it suppresses the initial stage of growth of follicles; secondly, suppresses FSH-dependent growth and breeding preantral and small antral follicles. It is believed that AMG is not under the control of the gonadotropic hormones (FSH, LH) and adequately reflects the number of follicles. Therefore, its definition is considered an important test as a marker to determine follicular ovarian reserve (the estimate of the number of functionally active follicles in ovaries of women i.e. the number of eggs in women at this point in time, which can be used for fertilization), to assess ovarian dysfunction and ovarian aging (Nazarenko, I. A., Mishieva N. G., Panchenko N. D., 2005). Lower values AMG indicate a decline in ovarian reserve. Syndrome giperandrogenii - state in some sense the opposite of premature ovarian insufficiency. Local increase of the level of androgens in the ovarian tissue leads to excessive initiation of follicular development, the number of primordial and primary follicles significantly increased, resulting in rises and the AMH level. Thus, this figure clearly reflects the degree of violation of the follicle Genesis in the ovaries (Bogdanov P.F., Karev, M. A., 2010). These findings were confirmed by our studies revealed a direct dependent shall be between the increased level of androgens in the blood plasma, increased levels of AMH and echographic features of ovarian cancer, in particular to increase their volume and number of follicles up to 8 mm in diameter. The inventive method eliminates the subjectivity, regardless of the age, emotional status and that allows the doctor with high accuracy according to the level of AMH in serum to determine the risk of development of ovarian dysfunction in the future, and to avoid overdiagnosis PCOS in adolescent girls, promptly appoint the most adequate pathogenetic therapy. This measure will help restore menstrual function and improvement of reproductive health of adolescent girls. Our studies have shown that AMH level in healthy adolescent girls in the control group ranged from 2.1 to 4.9 ng/ml and the average was 3.4±0.2 ng/ml. Patients with age of menarche at least 2 years, with the increase of androgens in the blood (testosterone, Androsterone or dehydroepiandrosterone), as well as manifestations of androgen dermopathy and normal menstrual cycle, or in patients without androgen of dermopathy, with the increase of androgens in the blood and irregular menstrual cycle, determine the level of AMH in the blood on day 3-5 of the menstrual cycle. When the values of AMH between 5.2 and above are regarded as grahamii development and progression, ovarian dysfunction; AMH level over 8.2 ng/ml in combination with the presence of sonographic signs multifollicular ovaries diagnosed as emerging PCOS. Detailed description of the method and examples of its specific implementation. Patients 15-17 years at risk for the development of PCOS on 3-5 day cycle produce blood serum in the morning on an empty stomach. The AMH level in the serum of patients determine enzyme-linked immunosorbent assay using a set of DSL-10-14400 ACTIVE® Mullerian Inhibiting Substance/Anti-Mullerian Hormone (MIS/AMH) Enzyme-Linked Immunosorbent (ELISA (USA). Standard mortars, conjugates, wash buffer is prepared according to the instructions to the set. All reagents and samples prior to analysis should be maintained at room temperature (~25°C) and mixed thoroughly before using careful turning. Make 20 µl of standards, controls and samples into the appropriate wells. Add 100 ál of working solution of buffer AMS GEN II in each cell, using a semi-automatic dispenser. Then incubated for 1 hour at ~25°C on an orbital shaker at 600-800 rpm Using an automatic plate washer, washed 5 times with washing buffer and dried tablet, turning it to a filtered paper. Next, add 100 ál of solution bioteknologi conjugate to each well, at the end of Incubus is AI 5 times washed tablet, as explained above. Then add 100 μl of a solution of streptavidin-enzyme conjugate into each well. Again at the end of the incubation carried out five times washing tablet and dried, turn on the filtered paper. Add 100 μl of chromogenic TMB solution into each well using a semi-automatic dispenser. Add 100 ál of stop solution to each well using a semi-automatic dispenser. Measure the optical density of the cells at 450 nm measuring the optical density of the microplate must be performed within 30 minutes after adding the stop reagent solution. Express AMH level in the serum of the patient in ng/L. When the value of the AMG higher to 5.2 ng/ml diagnose the possible risk of developing PCOS. The performance of the proposed method are confirmed by the following specific examples. Example 1 The patient Daria And society, 15 years old, suffering from disorders of the menstrual cycle from menarche type oligomenorrhea, hair growth in atypical places, acne. The girl from 2 pregnancies occurring with premature birth by caesarean section. History - inverted puberty. Menstrual cycle with 12 years after 60-90 days. About-but: hirsute number 14 points. At the time of examination on the 5th day of the menstrual cycle in girls level LH 11.2 mm/ml; FSH - 4.9 mm/ml; estradiol - 48 pgml; 17-GOP - 1.1 ng/ml; DHEA - 14,0 ng/ml; DHEA-S - 5,7 mg/ml; testosterone - 5.0 nmol/l; testosterone free and 6.7 PG/ml Ultrasound of the pelvic organs: volume right ovary - 13,9 cm3; volume left ovary 11,4 cm3in the projection of both ovaries many immature follicles up to 7-8 mm in diameter. The AMH level in the serum was 5.2 ng/ml, indicating that emerging PCOS. The diagnosis in accordance with the claimed invention, is consistent with the comprehensive evaluation of the condition of hormonal imbalance (for determining levels of luteinizing and follicle stimulating hormones, their relationships, and so on). Example 2 The patient Anastasia To the Islands, 16 years old, suffering from disorders of the menstrual cycle-type oligo-and amenorrhea for 3 years, acne. Perinatal history is not burdened. His mother had been a violation of the menstrual cycle in the pubertal period. Menstrual cycle with 12 years regularly since the age of 14, after 40-60 days. About-but: hirsute number - 8 points. At the time of the survey the girl LH levels to 10.7 mm/ml; FSH - 5.8 mm/ml; estradiol - 35 PG/ml; 17-GOP - 0.9 ng/ml; DHEA - 9.0 ng/ml; DHEA-S - 4,4 µg/ml; testosterone - 3.2 nmol/l; testosterone free to 5.7 PG/ml Ultrasound of the pelvic organs: volume right ovary - 8.7 cm3; volume left ovary 7.1 cm3in the projection of both ovaries many nez is elih follicles up to 6-7 mm in diameter. The AMH level in the blood serum of the patient was 6.3 ng/ml, indicating pubertal ovarian dysfunction. Example 3 The patient Anna F. Ko, 17 years old, suffering from irregular menstrual cycle from menarche, complaining of hair growth in atypical places. Menstrual cycle since the age of 14, menorrhagia alternate with oligomenorrhea. Perinatal history burdened. The pregnancy proceeded with preeclampsia in the second half. About-but: hirsute number - 10 points. At the time of the survey the girl the level of LH - 7.2 mm/ml; FSH - 4.1 mm/ml; estradiol - 48 PG/ml; 17-GOP - 1.3 ng/ml; DHEA - 14.7 ng/ml; DHEA-S - 6,4 mg/ml; testosterone - 3.2 nmol/l; testosterone free - of 8.7 PG/ml Ultrasound of the pelvic organs: volume right ovary is 11.9 cm3; volume left ovary 9.8 cm3in the projection of both ovaries many immature follicles up to 4-5 mm in diameter. The AMH level in the serum was 5.3 ng/ml, indicating that pubertal ovarian dysfunction. Example 4 The patient Ksenia N-VA, 16 years old, complains of hair growth in atypical places, acne. Menstrual cycle with 12 years 24-26 days. Perinatal history is not burdened. The mother suffered from hirsutism. About-but: hirsute number is 13 points. At the time of the survey the girl the level of LH - 6.3 mm/ml; FSH - 4.8 mm/ml; estradiol - 70 PG/ml; 17-GOP - 0.9 ng/ml; DHEA and 9.1 ng/ml; DHEA-S - 3,4 µg/ml; tests Eron - 2.2 nmol/l; testosterone free of 3.1 PG/ml Ultrasound of the pelvic organs: volume right ovary - 5,9 cm3; volume left ovary 6.1 cm3in the projection of both ovaries many immature follicles to 5-7 mm in diameter. The AMH level in the serum was 5.1 ng/ml, which indicated the absence of ovarian pathology. Example 5 (in dynamics 6 months) The patient Anastasia To the Islands, 17 years old, suffering from disorders of the menstrual cycle-type oligo-and amenorrhea for at least 3.5 years, acne. The menstrual cycle in 12 years, occasionally with 14 years of 40-90 days. About-but: hirsute number of 12 points. At the time of the survey the girl the level of LH - 14.2 mm/ml; FSH - 5.1 mm/ml; estradiol - 28 PG/ml; 17-GOP - 1.1 ng/ml; DHEA to 12.0 ng/ml; DHEA-S - 5,0 µg/ml; testosterone - 4.2 nmol/l; testosterone free of 4.9 PG/ml Ultrasound of the pelvic organs: volume right ovary - 8.9 cm3; volume left ovary 7.7 cm3in the projection of both ovaries many immature follicles up to 6-8 mm in diameter. The AMH level in the serum was 9.6 ng/ml Thus, the high level AMG, along with the increase of the index of LH/FSH=2,7:1, gives the right to assert the presence of the patient emerging PCOS. Example 6 (in dynamics 6 months) The patient Anna F. Ko, 17 years old, suffering from irregular menstrual cycle from menarche complaints on the growth of the ox is in atypical places. Menstrual cycle since the age of 14, menorrhagia alternate with oligomenorrhea. About-but: hirsute number of 12 points. At the time of the survey: LH - 13.2 mm/ml; FSH - 4.8 mm/ml; estradiol - 130 PG/ml; 17-GOP - 1.2 ng/ml; DHEA to 18.7 ng/ml; DHEA-S - 4,3 mg/ml; testosterone - 2.8 nmol/l; testosterone free to 7.4 PG/ml Ultrasound of the pelvic organs: volume right ovary and 14.9 cm3; volume left ovary 12.2 cm3in the projection of both ovaries many immature follicles to 7-9 mm in diameter. The level of AMH in serum amounted to 12.8 ng/ml, indicative of PCOS. Dynamic observation of the patient revealed an increase in the rate of AMG, the increase in the volume of both ovaries, index increase LH/FSH>3:1. By the present method were examined 102 patients aged 14 to 17 years with menstrual disorders and clinical manifestations of giperandrogenii. Median AMH level in the serum made 6.13 ng/ml (quartiles 2,87; 10,20 ng/ml). In the group with no disruption of the menstrual cycle the levels of AMH (n=20) in the serum of less than 4.1 ng/ml was observed in 18 people (90%). In the group with clinical signs of giperandrogenii and regular menstrual cycle (n=42) AMH level in the serum of not less than 1.8 ng/ml, but not more than 5.1 ng/ml was observed in 39 (92.8 per cent). In the group of clinical signs of giperandrogenii and menstrual CEC is a (n=40) AMH level in the serum of more than 6.7 ng/ml, but less of 24.5 ng/ml were found in 33 people (82,5%). In the group with the menstrual cycle and sonographic signs multifollicular ovaries (n=18) AMH level in the serum is more of 10.1 ng/ml were detected in 15 people (83,3%). Thus, the study of the level of AMH in serum in adolescent girls with menstrual disorders showed that it is highly informative and objective criterion and accurate diagnostic marker for PCOS. The accuracy of the proposed method reaches of 91.6%. Based on the foregoing, the inventive method for the diagnosis of PCOS in adolescent girls compared to existing, has the following advantages: 1. The method allows for early diagnosis of PCOS to select timely preventive treatment. 2. This method is objective, not dependent on age and emotional status of the patient. 3. The proposed method has a sufficiently high accuracy, simple in execution and will find wide application in gynecological endocrinology and practice. A method for the diagnosis of menstrual function on the background of polycystic ovary syndrome in adolescent girls through the study of hormones in the blood, characterized in that adolescent girls on day 3-5 of the menstrual cycle determined in serum by the method of enzyme-linked immunosorbent analysis is and the level antimullerian hormone, and if its value exceeds that of 5.2 ng/ml, diagnose menstrual function on the background of polycystic ovary syndrome.
|